We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

36 hedge funds and large institutions have $28.5M invested in Spruce Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less funds holding

Funds holding: 43 → 36 (-7)

17% less capital invested

Capital invested by funds: $34.4M → $28.5M (-$5.86M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

60% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 15

Holders
36
Holders Change
-7
Holders Change %
-16.28%
% of All Funds
0.61%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
6
Reduced
15
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$325K
2
Morgan Stanley
Morgan Stanley
New York
+$84.2K
3
E
Ergoteles
New York
+$71.6K
4
Renaissance Technologies
Renaissance Technologies
New York
+$67.9K
5
MAM
Marquette Asset Management
Minnesota
+$39.7K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$638K
2
BCM
Bridgeway Capital Management
Texas
-$318K
3
JP Morgan Chase
JP Morgan Chase
New York
-$194K
4
State Street
State Street
Massachusetts
-$192K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$5K -$3.97K -31 -44%
Bank of America
27
Bank of America
North Carolina
$5K -$3.46K -27 -42%
Wells Fargo
28
Wells Fargo
California
$2K -$6.53K -51 -78%
Federated Hermes
29
Federated Hermes
Pennsylvania
$2K +$1.67K +13 New
Fidelity Investments
30
Fidelity Investments
Massachusetts
$1K -$11.1K -87 -94%
Citigroup
31
Citigroup
New York
$1K -$1.41K -11 -69%
Legal & General Group
32
Legal & General Group
United Kingdom
$1K – – –
JP Morgan Chase
33
JP Morgan Chase
New York
– -$194K -1,512 Closed
Charles Schwab
34
Charles Schwab
California
– -$38K -246 Closed
State Board of Administration of Florida Retirement System
35
State Board of Administration of Florida Retirement System
Florida
– -$35K -233 Closed
CSS
36
Cubist Systematic Strategies
Connecticut
– -$27K -176 Closed
Deutsche Bank
37
Deutsche Bank
Germany
– -$24K -164 Closed
Nuveen
38
Nuveen
North Carolina
– -$24K -155 Closed
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
– -$10.1K -79 -99%
AIG
40
American International Group
New York
– -$9K -57 Closed
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
– -$8K -52 Closed
PHK
42
Point72 Hong Kong
Hong Kong
– -$6K -38 Closed
AB
43
Amalgamated Bank
New York
– -$2K -14 Closed
AIP
44
Ameritas Investment Partners
Nebraska
– -$1K -8 Closed
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
– -$769 -6 -75%
CAL
46
Capital Advisors Ltd
Ohio
– +$256 +2 New
1
2

SPRB Hedge Fund Activity: Q2 2022 in Review

36 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2022, worth a combined $28.5M — down 17% from $34.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of SPRB and 6 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 6 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $325K. The largest seller was BlackRock, cutting an estimated $638K.

  • 36 institutional investors held Spruce Biosciences (SPRB) as of Q2 2022, down from 43 in Q1 2022.
  • Funds reported $28.5M of Spruce Biosciences stock for Q2 2022, down 17% quarter-over-quarter.
  • 6 funds opened new Spruce Biosciences positions in Q2 2022 and 11 closed out, a net change of -5 holders.
  • The largest Spruce Biosciences buyer in Q2 2022 was Millennium Management, an estimated $325K added.
  • The largest Spruce Biosciences seller in Q2 2022 was BlackRock, an estimated $638K sold.

Based on aggregated 13F filings for Q2 2022.